MRNA · News · 20260730N

Market Demand Trends

Moderna, Inc. · 2026-07-30 · Importance 44 · Surprise 24

Moderna remains heavily dependent on demand for COVID-19 vaccines, particularly its flagship Spikevax product, as pandemic-era demand has declined. Third-party coverage identifies vaccine sales as a central focus for the second quarter and describes the company as working to diversify beyond COVID-19 vaccines. Seasonal influenza demand could provide a new respiratory-market opportunity if Moderna’s mRNA-1010 vaccine is approved.

Key facts

• GuruFocus' GF Value™ shows Moderna trading at $57.49 against an intrinsic value of $22.79 per share, implying it is 152.3% overvalued. source
• Moderna's shares were down 21.8% over the last month heading into earnings. source